Shenzhen Salubris Pharmaceuticals Co: 2024 revenue rose 19.22% to ¥4.01B, net profit up 3.71%, with strong R&D and cash dividend

About this update from Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A

Revenue grew 19.22% to ¥4.01 billion in 2024, with net profit up 3.71% to ¥601.57 million. New product launches and strong R&D investment drove growth, while cash flow and margins improved. A cash dividend of ¥5.00 per 10 shares is proposed.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A